Reported 5 months ago
The article discusses how billionaire fund managers are increasingly investing in Pfizer stock due to its recent decline in value, with notable figures like Steve Cohen, Jeff Yass, John Overdeck, and Jason Siegel acquiring significant shares in the first quarter of the year. The attraction stems from Pfizer's strong cash flow generated by its COVID-19 products, reinvestments in potential blockbusters like Seagen, and the growth potential of new cancer drugs like Padcev and Lorbrena. With Pfizer's solid dividend yield, steady dividend increases, and promising profit growth outlook, long-term investors are advised that investing in Pfizer at its current value could yield favorable returns.
Source: YAHOO